Hematology Market: Size, Share, Key Developments, Innovations, and Opportunities Through 2031

Hematology Market Overview

The global hematology market is projected to grow at a CAGR of approximately 3–5% through 2027. Demand is propelled by the rapid uptake of artificial-intelligence enabled automation, the growing burden of hematologic cancers and anemia, and wider availability of point-of-care (POC) testing platforms. Automated platforms boost laboratory throughput and cut human-error rates, while cloud-connected middleware helps laboratories offset skilled-labor shortages. At the same time, high-parameter flow cytometers improve measurable residual-disease detection, sustaining premium analyzer sales despite capital-intensity concerns. Supply-chain risks around porcine-sourced heparin and data-privacy regulations for connected instruments temper near-term momentum but are unlikely to derail the broader growth trajectory. North America retains volume leadership, yet Asia-Pacific is accelerating on the back of health-infrastructure upgrades and local production investments.

Download Sample Copy: https://meditechinsights.com/global-hematology-market/request-sample/

Hematology is a medical specialty focused on the study of blood, blood-forming organs, and related disorders. It encompasses a wide range of benign and malignant conditions affecting red blood cells, white blood cells, platelets, and the coagulation system in both adults and children. Hematology specialists are involved in the research, diagnosis, and treatment of conditions such as anemia, hemophilia and other bleeding disorders, blood clots, sickle cell disease, and hematological malignancies including leukemia, lymphoma, and myeloma.

Hematology Market Trends and Insights

Growth in AI-enabled Automated CBC Platforms

Low-cost AI flow-cytometry prototypes developed at Rice University demonstrate performance comparable to high-end systems, lowering entry barriers for resource-constrained facilities. The FDA’s reclassification of automated hemoglobin systems to Class II further eases U.S. market access[1]. Machine-learning algorithms now deliver sub-second cell-morphology recognition, shrinking turnaround times and supporting adoption in high-volume hospitals. Cloud analytics also help labs benchmark quality metrics across networks, reinforcing procurement arguments. Collectively, these gains elevate analyzer utilization rates and underpin recurring reagent revenues, keeping the hematology market on a firm growth path.

Rising Incidence of Hematologic Cancers & Anemia

The Leukemia & Lymphoma Society counts 1.70 million U.S. residents living with blood cancers, with 187,740 new cases expected in 2024[2]. Ageing populations in developed economies drive prevalence, while improved survival extends monitoring cycles that rely on routine CBC and flow-cytometry panels. Progress in targeted therapies widens patient eligibility, lifting test volumes. Advanced economies shoulder the largest caseloads, yet emerging markets are catching up as diagnostic infrastructure expands. The sustained clinical burden translates into predictable demand, anchoring the hematology market against economic volatility.

Expansion of Decentralized POC Hematology Testing

The FDA cleared the first POC hepatitis C RNA assay in 2024, signaling regulatory support for near-patient diagnostics. Portable Hb devices such as Masimo’s SpHb monitor enable real-time hemoglobin tracking without venipuncture. CMS amended rules for rural clinics, removing obligatory hemoglobin tests from central-lab panels and freeing providers to adopt POC workflows. Tele-health integration allows remote specialists to review results instantaneously, shrinking treatment delays. These structural shifts move a share of volumes away from hospital cores into outpatient and community settings, broadening the hematology market footprint.

Download Sample Copy: https://meditechinsights.com/global-hematology-market/request-sample/

Surge in Complex Therapies Needing Advanced Blood Monitoring

CAR-T protocols and gene therapies demand 19-color flow panels for residual-disease tracking, pushing laboratories toward higher-parameter cytometers. The FDA approval of Duvyzat for Duchenne muscular dystrophy mandates platelet monitoring, reinforcing comprehensive hematology panels during therapy. Beckman Coulter’s DxFLEX clearance underscores industry responsiveness, bringing 13-color immunophenotyping into routine clinical use. As biopharma pipelines swell with precision treatments, real-time hematologic monitoring becomes integral, stimulating premium-segment growth within the hematology market.

Impact of COVID-19 on the Global Hematology Market

The COVID-19 pandemic had a positive impact on the hematology market, as hematological parameters became critical for assessing and managing COVID-19 patients worldwide. Demand for hematology analyzers increased significantly, as these systems were widely used for tests such as complete blood counts, blood level measurements, and detailed blood sample analyses.

Since the lungs were the primary organs affected by COVID-19, hematology testing played an essential role in monitoring red blood cell (RBC) counts and oxygen transport. Damage to the alveoli disrupted gas exchange, impairing the ability of red blood cells to carry oxygen. As a result, hematology tests became vital for evaluating disease severity and patient outcomes during the pandemic.

Technological Advancements Driving Market Growth

Ongoing technological innovation remains a major force propelling the global hematology market. Manufacturers continue to introduce advanced analyzers that improve workflow efficiency, accuracy, and throughput in laboratories.

For example, in May 2023, Siemens Healthineers launched the next-generation Atellica HEMA 570 and Atellica HEMA 580 analyzers, designed for high-volume testing with intuitive user interfaces and enhanced automation connectivity. Similarly, in July 2022, HORIBA Medical expanded its Yumizen H500 and H550 product family with compact benchtop analyzers offering improved performance, new functionalities, and added value for laboratories.

As highlighted by a director at a leading U.S.-based hematology analyzer manufacturer, the increasing incidence of blood disorders, rapid technological advancements, and the ongoing digital transformation of hematology laboratories are key growth drivers. In the European Union alone, an estimated 80 million people are affected by blood disorders.

AI-Powered Hematology Analyzers Enhancing Diagnostic Capabilities

Traditional hematology analyzers often provide limited diagnostic insights, while the growing volume of laboratory data can overwhelm clinicians. AI-powered automatic hematology analyzers address this challenge by applying artificial intelligence to convert complex data into clinically meaningful insights. These systems help reduce turnaround times, minimize misclassifications, and lower the workload for healthcare professionals.

An example is the DH-615 hematology analyzer from Dymind Biotechnology, which combines fluorescent nucleic acid staining with the company’s proprietary AI Cube technology. By integrating 6-DIFF with reticulocyte (RET) analysis, the system significantly improves abnormal cell detection and enhances the assessment of hematological diseases.

Browse Report: https://meditechinsights.com/global-hematology-market/

Competitive Landscape of the Hematology Market

The global hematology market is highly competitive, with the presence of several established players, including:

• Sysmex Corporation
• Beckman Coulter (Danaher Corporation)
• Siemens Healthineers
• Abbott
• Mindray
• Nihon Kohden
• Boule Diagnostics
• Bio-Rad Laboratories
• HORIBA
• Drew Scientific

Growth Strategies Adopted by Market Leaders

Leading companies in the hematology market employ a combination of organic and inorganic growth strategies, such as new product launches, partnerships, and collaborations, to strengthen their market position.

For instance, in July 2022, Beckman Coulter partnered with Scopio Labs to accelerate the adoption of digital cell morphology platforms in hematology. In March 2022, Mindray introduced the BC-700 Series, a compact and integrated CBC and ESR hematology analyzer designed for small- to mid-sized laboratories.

Related Report:

Pain Management Devices Market   https://www.pharmiweb.com/press-release/2026-05-12/pain-management-devices-market-emerging-as-a-high-growth-healthcare-investment-space-through-2030

Anti-snoring Devices Market https://www.pharmiweb.com/press-release/2026-05-12/anti-snoring-devices-market-revenue-modeling-and-strategic-forecast-2026-to-2031

Hospital Information Systems Market          https://www.pharmiweb.com/press-release/2026-05-14/hospital-information-systems-market-size-is-expected-to-witness-substantial-growth-at-a-significant-cagr-by-2031

Bunion Surgery Market          https://www.pharmiweb.com/press-release/2026-05-14/bunion-surgery-market-growth-outlook-segmentation-industry-trends-2026-2031   

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com